Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 6 clients • 10 examiners • 7 art units • 0 of 10 (0%) have an AI response strategy ready
Blanchard Horton PLLC operates in the Biotechnology & Pharmaceuticals sector, having managed 422 career applications. The firm has achieved a resolved allowance rate of 89.51 percent, which is a strong indicator of its success. Currently, there are 6 pending office actions under the firm's management relative to its 422 career applications.
The firm averages 2.65 office actions per allowance, reflecting an efficient prosecution process that typically involves multiple rounds of communication with the patent office. This 2.65 average, combined with the 89.51 percent resolved allowance rate, suggests an effective approach to securing patent rights. With 422 career applications, the firm has established a solid presence. The 6 pending office actions and the 2.65 office actions per allowance metric provide a detailed look at the firm's current and historical prosecution performance, offering valuable insights into its typical outcomes and efficiency.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (40%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLOMAN, NANNETTE | 1 | 60.7% | +22.8% |
| AMPONSAH, OSEI K | 1 | 72.4% | +33.1% |
| SPIES, BRADLEY R | 1 | 74.2% | +20.5% |
| MAEWALL, SNIGDHA | 1 | 58.8% | +10.5% |
| BARFIELD, ANTHONY DERRELL | 1 | 80.1% | +13.9% |
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
| MARMOR II, CHARLES ALAN | 1 | 12.4% | +25.7% |
| CALEY, MICHAEL H | 1 | 65.1% | +13.0% |
| WAX, ROBERT A | 1 | 25.0% | +3.9% |
| WHEELER, THURMAN MICHAEL | 1 | 45.8% | +23.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615236 | MICROEMULSION DELIVERY SYSTEMS INCORPORATED INTO GUMMY CONFECTIONS | WEBB, WALTER E | 5d overdue |
| 18132589 | Drug Delivery Cannula with Continuous Glucose Monitoring Capability | MARMOR II, CHARLES ALAN | 33d |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | WAX, ROBERT A | 34d |
| 18938462 | Fire Resistant Electrolyte for Lithium Batteries | AMPONSAH, OSEI K | — |
| 18924304 | Electro-Pressure Membrane Method for Recovery and Concentration of Lithium from Aqueous Sources | SPIES, BRADLEY R | — |
| 18813727 | Sofa with Swivel Feature | BARFIELD, ANTHONY DERRELL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17765283 | Fibre Optic Connector | CALEY, MICHAEL H | 330d overdue |
| 17672894 | Microemulsion Delivery Systems for Alcohol-Soluble Species Including Nonderivatized Hormones | WHEELER, THURMAN MICHAEL | 38d overdue |
| 18615236 | MICROEMULSION DELIVERY SYSTEMS INCORPORATED INTO GUMMY CONFECTIONS | WEBB, WALTER E | 5d overdue |
| 18132589 | Drug Delivery Cannula with Continuous Glucose Monitoring Capability | MARMOR II, CHARLES ALAN | 33d |
| 19083881 | Means For Mitochondrial Performance Enhancement | HOLLOMAN, NANNETTE | — |
| 18938462 | Fire Resistant Electrolyte for Lithium Batteries | AMPONSAH, OSEI K | — |
| 18924304 | Electro-Pressure Membrane Method for Recovery and Concentration of Lithium from Aqueous Sources | SPIES, BRADLEY R | — |
| 18891496 | Solid Binding Composition for Toxin Excretion Enhancement | MAEWALL, SNIGDHA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Quicksilver Scientific, Inc. | 5 |
| American Hyperform, Inc. | 1 |
| Aqueous Resources LLC | 1 |
| Kenneth Charles Design, LLC | 1 |
| Pacific Diabetes Technologies, Inc. | 1 |
| Ridgemount Technologies Limited | 1 |
| Art Unit | Apps |
|---|---|
| 1752 | 1 |
| 3636 | 1 |
| 1612 | 1 |
| 3791 | 1 |
| 2871 | 1 |
| 1615 | 1 |
| 1619 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19083881 | Means For Mitochondrial Performance Enhancement | Quicksilver Scientific, Inc. | HOLLOMAN, NANNETTE | §103 | Non-Final OA | — | Pending | Mar 19, 2025 | |
| 18938462 | Fire Resistant Electrolyte for Lithium Batteries | American Hyperform, Inc. | AMPONSAH, OSEI K | 1752 | §102§103 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18924304 | Electro-Pressure Membrane Method for Recovery and Concentration of Lithium from Aqueous Sources | Aqueous Resources LLC | SPIES, BRADLEY R | §102§103Other | Non-Final OA | — | Pending | Oct 23, 2024 | |
| 18891496 | Solid Binding Composition for Toxin Excretion Enhancement | Quicksilver Scientific, Inc. | MAEWALL, SNIGDHA | §103DP | Non-Final OA | — | Pending | Sep 20, 2024 | |
| 18813727 | Sofa with Swivel Feature | Kenneth Charles Design, LLC | BARFIELD, ANTHONY DERRELL | 3636 | §102§103 | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18615236 | MICROEMULSION DELIVERY SYSTEMS INCORPORATED INTO GUMMY CONFECTIONS | Quicksilver Scientific, Inc. | WEBB, WALTER E | 1612 | §103§112 | Final Rejection | 5d overdue | Pending | Mar 25, 2024 |
| 18132589 | Drug Delivery Cannula with Continuous Glucose Monitoring Capability | Pacific Diabetes Technologies, Inc. | MARMOR II, CHARLES ALAN | 3791 | §103 | Final Rejection | 33d | Pending | Apr 10, 2023 |
| 17765283 | Fibre Optic Connector | Ridgemount Technologies Limited | CALEY, MICHAEL H | 2871 | §103 | Non-Final OA | 330d overdue | Pending | Mar 30, 2022 |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | Quicksilver Scientific, Inc. | WAX, ROBERT A | 1615 | §103 | Non-Final OA | 34d | Pending | Mar 29, 2022 |
| 17672894 | Microemulsion Delivery Systems for Alcohol-Soluble Species Including Nonderivatized Hormones | Quicksilver Scientific, Inc. | WHEELER, THURMAN MICHAEL | 1619 | §112Other | Final Rejection | 38d overdue | Pending | Feb 16, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial